BioNTech Shares Tumble After BMO Downgrade Amid Vaccine Demand Woes and Trial Halt

FRANKFURT — Shares of BioNTech SE plummeted in premarket trading on the NASDAQ following a downgrade by BMO Capital Markets, which also slashed its price target for the German biotechnology firm. The sell-off reflected growing investor concerns over slowing global demand for COVID-19 vaccines and setbacks in the company's broader oncology pipeline.

BMO Capital downgraded the stock from "Outperform" to "Market Perform," citing a deteriorating outlook for BioNTech's core vaccine business. The analyst firm noted that inventory levels in Germany are currently being drawn down as supply outpaces immediate demand, a trend expected to persist through the remainder of 2026. This inventory overhang, combined with a significant contraction in global orders for pandemic-era vaccines, has pressured revenue projections for the company.

Compounding the vaccine headwinds was news regarding BioNTech's oncology division. The company announced the termination of its Phase 2 clinical trial for autogene cevumeran, an investigational cancer therapy designed to target specific tumor mutations. The decision to halt the study follows a review of interim data that failed to meet predefined efficacy endpoints. Autogene cevumeran had been positioned as a key growth driver beyond the company's vaccine portfolio, and its discontinuation removes a potential long-term revenue stream.

The dual impact of weakening vaccine sales and the oncology setback has triggered a sharp reassessment of BioNTech's valuation by Wall Street analysts. While BioNTech continues to advance other candidates in its pipeline, including mRNA-based treatments for respiratory syncytial virus and influenza, the immediate market reaction highlighted the fragility of the company's transition from a pandemic-focused entity to a diversified biopharma player.

Trading activity remained volatile as investors digested the analyst note. The price cut by BMO Capital was among the most significant adjustments in the sector this week, signaling a broader shift in sentiment toward companies heavily reliant on post-pandemic vaccine markets. Analysts pointed out that while BioNTech maintains a strong cash position, the path to profitability without its flagship vaccines or successful oncology drugs remains uncertain.

Market observers are now waiting to see if other major investment banks will follow BMO's lead with similar downgrades. Additionally, questions remain regarding how quickly BioNTech can pivot its manufacturing capacity away from COVID-19 products and toward its next-generation therapies. The company has not yet issued a formal statement addressing the specific timeline for future pipeline updates or strategic shifts in response to the terminated trial.